Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

NCT ID: NCT05458258

Last Updated: 2025-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

239 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2025-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia Leukemia, Myeloid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults (age 60+) with Newly Diagnosed AML

This group will consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo chemotherapy and/or receive cancer drugs (as part of standard care). Participants in this group will receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia.

Bioelectrical Impedence Analysis Device

Intervention Type DEVICE

A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.

6 Minute Walk Test

Intervention Type OTHER

Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.

Computed Tomography Scans to Measure Skeletal Muscular Index

Intervention Type DIAGNOSTIC_TEST

Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).

Blood Test/Blood Draw

Intervention Type DIAGNOSTIC_TEST

Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.

Hand Grip Strength Test

Intervention Type OTHER

Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.

Healthy Control Group: Adults with AML (age 60+) in Good Health

This group will also consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo induction therapy and/or receive cancer drugs to treat their AML (as part of standard care). Participants in this group will also receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia. Participants in this group will receive the same assessment as participants in the first study group -- the only difference is that participants in this group have been determined to be healthier than those in the first study group according to clinical assessments.

Bioelectrical Impedence Analysis Device

Intervention Type DEVICE

A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.

6 Minute Walk Test

Intervention Type OTHER

Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.

Computed Tomography Scans to Measure Skeletal Muscular Index

Intervention Type DIAGNOSTIC_TEST

Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).

Blood Test/Blood Draw

Intervention Type DIAGNOSTIC_TEST

Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.

Hand Grip Strength Test

Intervention Type OTHER

Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bioelectrical Impedence Analysis Device

A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.

Intervention Type DEVICE

6 Minute Walk Test

Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.

Intervention Type OTHER

Computed Tomography Scans to Measure Skeletal Muscular Index

Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).

Intervention Type DIAGNOSTIC_TEST

Blood Test/Blood Draw

Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.

Intervention Type DIAGNOSTIC_TEST

Hand Grip Strength Test

Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Older Adult patients (greater than or equal to 60 years of age)
* New diagnosis of acute myeloid leukemia (AML)
* Receiving induction therapy (intensive or low intensity therapy)
* Willing and able to provide written informed consent

Exclusion Criteria

* Presence of a pacemaker or defibrillator.
* Participants who are pregnant at the time of enrollment.
* Anyone unable/unwilling to follow protocol requirements
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Chicago

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wendy Stock, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB22-0397

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.